We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Uterine Fibroid Embolization Results in Fewer Complications

By HospiMedica International staff writers
Posted on 11 Apr 2019
Uterine fibroid embolization (UFE) can treat uterine fibroids with fewer complications than surgical myomectomy, according to a new study.

The retrospective study, by researchers at Kaiser Permanente Southern California (KPSC; Pasadena, USA) involved 863 patients with uterine fibroids treated from 2008 to 2015; of these, 451 patients underwent UFE, and the rest a myomectomy. More...
The patients in the UFE group were older (mean age 45 years) than the myomectomy group (39 years), and more of them had multiple and smaller fibroids. The study results showed that women who had myomectomy had a 2.9% rate of blood transfusion, significantly higher than the 1.1% rate for women who had UFE; but 27 patients in the UFE group had adenomyosis, compared to eight patients in the myomectomy group.

In women with pre-procedural anemia, both groups experienced a statistically significant improvement in mean hemoglobin one year after the initial procedure. UFE also resulted in a significantly higher rate of symptomatic improvement in menorrhagia (75.4%) than in the myomectomy group (49.5%). Overall secondary intervention and miscarriage rates were not significantly different between the two groups. The study was presented at the Society of Interventional Radiology (SIR) annual scientific meeting, held during March 2019 in Austin (TX, USA).

“Women with uterine fibroids often are not fully informed of their treatment options, or lack understanding. This point was brought home in a recent survey showing that more than two in five women who have been diagnosed with uterine fibroids have never heard of UFE,” said lead author and study presenter Jemianne Bautista-Jia, PhD. “Women have multiple options available to treat uterine fibroids, and UFE is a beneficial option. UFE is minimally invasive, produces less pain, requires a shorter recovery time, and allows women to get back to their lives sooner.”

A uterine fibroid (leiomyomata) is a benign tumor that originates from smooth muscle (myometrium) in the uterus. The fibroids are often multiple, and if the uterus contains too many to count, it is referred to as diffuse uterine leiomyomatosis. Uterine fibroids are the most common benign tumors in females and typically found during the middle and later reproductive years. While most are asymptomatic, they can grow and cause heavy and painful menstruation, painful sexual intercourse, and urinary frequency and urgency.

Related Links:
Kaiser Permanente Southern California


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Medical Adhesive
MED 5570U
Medical Examination & Procedure Light
Vega 80
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image: The findings suggest that hematopoietic cell transplantation may benefit patients with Shwachman-Diamond syndrome soon after high-risk features are detected, before advanced malignancy develops. (Image Credit: Shutterstock)

Early Stem Cell Transplantation May Improve Survival in Rare Inherited Bone Marrow Disorder

Shwachman-Diamond syndrome (SDS) is a rare inherited bone marrow disorder that can progress to severe hematologic disease. More than 90% of affected children survive beyond age 20, but fewer than 30% live... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.